Ravulizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Complement component 5 |
| Clinical data | |
| Pronunciation | rav" ue liz' ue mab |
| Trade names | Ultomiris |
| Other names | ALXN1210, ravulizumab-cwvz |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619014 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Drug class | Complement inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | various proteases |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6430H9888N1696O2028S48 |
| Molar mass | 144938.56 g·mol−1 |
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of complement component 5 (C5).[7][6]
Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tissues), blood clots, and impaired bone marrow function (not making enough blood cells).[8] In paroxysmal nocturnal hemoglobinuria, proteins known as the "complement system", which is part of the immune system, become overactive because of a genetic mutation and start to attack the patients' own red blood cells.[7] Ravulizumab is a monoclonal antibody (a type of protein) designed to attach to the C5 protein, which is part of the complement system.[7] By attaching to the C5 protein, the medicine blocks its effect and thereby reduces the destruction of red blood cells.[7]
- ^ "Ultomiris". Therapeutic Goods Administration (TGA). 26 May 2022. Retrieved 9 March 2024.
- ^ "Ultomiris Product information". Health Canada. Retrieved 29 May 2022.
- ^ "Summary Basis of Decision (SBD) for Ultomiris". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ "Regulatory Decision Summary for Ultomiris". Drug and Health Products Portal. 6 January 2023. Retrieved 1 April 2024.
- ^ "Ultomiris 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 18 October 2020. Retrieved 12 October 2020.
- ^ a b "Ultomiris- ravulizumab solution, concentrate". DailyMed. 20 March 2020. Retrieved 1 May 2020.
- ^ a b c d e Cite error: The named reference
Ultomiris EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
FDA PR 20210607was invoked but never defined (see the help page).